Case Report Shows Carbimazole's ‘Triple-Hit’ - Top-Institutions - MDSpire

Case Report Shows Carbimazole's ‘Triple-Hit’

Diffuse alveolar hemorrhage with coexistent antiphospholipid syndrome complicated anticoagulation therapy and created competing bleeding and thrombosis risks.

  • By

  • Andrea Surnit

  • April 1, 2026

  • 3 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Rheumatology
    • Nephrology
    • Pulmonology
    • Hematology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Rheumatology
    • Immunology
    • Nephrology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Rheumatology
    • Pulmonology
    • Nephrology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Rheumatology
    • Immunology
    • Nephrology

  • #5

    National Institutes of Health (NIH) Clinical Center
    National Institutes of Health (NIH) Clinical Center

    Bethesda, MD

    Key Differentiators

    • Immunology
    • Rheumatology
    • Nephrology

Original Source(s)

Case Report Shows Carbimazole's ‘Triple-Hit’

  • by Andrea Surnit

  • April 1, 2026

Related Content

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Dupilumab Gains Pediatric CSU Approval

Targets type 2 inflammation in a population with limited treatment options